BRPI0923652A2 - diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 - Google Patents

diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Info

Publication number
BRPI0923652A2
BRPI0923652A2 BRPI0923652A BRPI0923652A BRPI0923652A2 BR PI0923652 A2 BRPI0923652 A2 BR PI0923652A2 BR PI0923652 A BRPI0923652 A BR PI0923652A BR PI0923652 A BRPI0923652 A BR PI0923652A BR PI0923652 A2 BRPI0923652 A2 BR PI0923652A2
Authority
BR
Brazil
Prior art keywords
treatment
cancer diagnosis
lgr7 antibody
lgr7
antibody
Prior art date
Application number
BRPI0923652A
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Shinichi Funahashi
Yuriko Uehara
Original Assignee
Forerunner Pharma Res Co Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Res Co Ltd, Univ Tokyo filed Critical Forerunner Pharma Res Co Ltd
Publication of BRPI0923652A2 publication Critical patent/BRPI0923652A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0923652A 2008-12-26 2009-12-25 diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 BRPI0923652A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008333149 2008-12-26
PCT/JP2009/071524 WO2010074192A1 (ja) 2008-12-26 2009-12-25 抗lgr7抗体を用いる癌の診断および治療

Publications (1)

Publication Number Publication Date
BRPI0923652A2 true BRPI0923652A2 (pt) 2016-10-18

Family

ID=42287797

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923652A BRPI0923652A2 (pt) 2008-12-26 2009-12-25 diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Country Status (12)

Country Link
US (2) US20120014870A1 (pt)
EP (1) EP2377891B1 (pt)
JP (1) JP5801557B2 (pt)
KR (1) KR20110099762A (pt)
CN (1) CN102395603A (pt)
AU (1) AU2009331178A1 (pt)
BR (1) BRPI0923652A2 (pt)
CA (1) CA2748990A1 (pt)
MX (1) MX2011006908A (pt)
RU (1) RU2011131071A (pt)
SG (1) SG172427A1 (pt)
WO (1) WO2010074192A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175692A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
CN102636655B (zh) * 2012-05-10 2014-07-23 苏州大学附属第一医院 一种荧光原位微量淋巴毒检测方法和试剂盒
PL3049489T3 (pl) * 2013-09-27 2019-02-28 Stora Enso Oyj Kompozycja zawierająca ligninę i związek epoksydowy do powlekania i sposób jej wytwarzania i jej zastosowanie
KR20170056521A (ko) 2014-09-16 2017-05-23 오바사이언스, 인크. 항-vasa 항체, 및 이것의 제조 및 사용 방법
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HUE055207T2 (hu) * 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
EP3559045A4 (en) * 2016-12-23 2020-08-19 REMD Biotherapeutics, Inc. IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
CN113692284A (zh) * 2018-11-20 2021-11-23 海德堡大学 用于治疗和预防心力衰竭的松弛素受体1
CN114230666B (zh) * 2021-12-20 2022-09-02 南京诺唯赞生物科技股份有限公司 一种t7 rna聚合酶的单克隆抗体及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69941330D1 (de) 1998-03-26 2009-10-08 Univ R Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU1185502A (en) * 2000-10-04 2002-04-15 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002324727A1 (en) * 2001-08-17 2003-03-03 The Board Of Trustees Of The Leland Stanford Junior University Mammalian relaxin receptors
WO2003093827A2 (en) * 2002-05-02 2003-11-13 Bayer Healthcare Ag Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7)
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
US20090215711A1 (en) 2004-04-30 2009-08-27 Sagres Discovery, Inc. Novel compositions and methods in cancer
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
DE602008006041D1 (de) 2007-01-30 2011-05-19 Forerunner Pharma Res Co Ltd CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS

Also Published As

Publication number Publication date
US20200157231A1 (en) 2020-05-21
CN102395603A (zh) 2012-03-28
CA2748990A1 (en) 2010-07-01
EP2377891A1 (en) 2011-10-19
EP2377891B1 (en) 2018-11-21
SG172427A1 (en) 2011-07-28
AU2009331178A1 (en) 2011-08-11
KR20110099762A (ko) 2011-09-08
JP5801557B2 (ja) 2015-10-28
RU2011131071A (ru) 2013-02-10
EP2377891A4 (en) 2012-08-29
US20120014870A1 (en) 2012-01-19
JPWO2010074192A1 (ja) 2012-06-21
MX2011006908A (es) 2011-10-06
WO2010074192A1 (ja) 2010-07-01

Similar Documents

Publication Publication Date Title
BRPI0719202A2 (pt) Diagnóstico e tratamento de câncer usando anticorpo antiereg
PT2247620T (pt) Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
IL258794B (en) Methods and compositions for diagnosis and treatment of cancer
PT2474557E (pt) Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BRPI0822064A2 (pt) Dispositivos de imageamento fotoacústico e métodos de imageamento
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
EP2207803A4 (en) Cd9-specific human antibodies
BRPI0810206A2 (pt) Método de tratar câncer
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
IL213116B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BR112012005594A2 (pt) tratamento de câncer
SMT201500186B (it) Autoanticorpi umani anti-alfa-sinucleina
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0910854A2 (pt) métodos de tratamento
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
PL2282675T3 (pl) System do zabiegu kosmetycznego i obrazowania
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2320045A4 (en) APPARATUS FOR TREATING EXHAUST GAS
BRPI0919748A2 (pt) dipositivo de tratamento
CY2016053I1 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
BRPI0923652A2 (pt) diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE A PETICAO NO 020130046756/RJ DE 28.05.2013 SEJA CONHECIDA, DEVERA SER APRESENTADO DOCUMENTO DE PROCURACAO, OUTORGADO POR TODOS OS DEPOSITANTES, NO ORIGINAL OU COPIA AUTENTICADA, DANDO AO PROCURADOR PODERES PARA DESISTIR DO PEDIDO.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 020130046756/RJ DE 28/05/2013, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO FOI CUMPRIDA A EXIGENCIA 6.7 PUBLICADA NA RPI 2224 DE 20/08/2013.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]